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We explored the potential for EXPAREL to interact with lidocaine. Sixty (60) male Yucatan Swine were randomized into 20 groups
(N = 3/group). EXPAREL (2 or 4mg/kg) and/or lidocaine HCl solution 1% or 2% (with epinephrine 1:200,000) were injected
subcutaneouslyalonga5cmvirtualincisionline.Theeﬀectsonthepharmacokineticsofbupivacaineandlidocainewereexamined
when 5, 10, 20, and 40 minutes had passed between administration of lidocaine and EXPAREL. Systemic exposure to lidocaine was
increased (AUC0−24hr by 48%; Cmax by 1,640%) when lidocaine (4mg/kg) was followed 5 minutes later by EXPAREL (4mg/kg)
compared to lidocaine administered alone. Plasma bupivacaine was increased (AUC0−24hr by 50–95%; Cmax by 67–1,000%) when
lidocaine (4mg/kg) was followed 5 or 10 minutes later by EXPAREL (4mg/kg) compared to EXPAREL alone. While EXPAREL
should not be admixed with lidocaine, this study shows that local administration of EXPAREL after at least 20 minutes following
local administration of lidocaine did not increase the release of either drug.
1.Introduction
DepoFoam bupivacaine (EXPAREL, bupivacaine liposome
injectable suspension) is for single-dose inﬁltration into the
surgical site to produce postsurgical analgesia. Among new
drug delivery systems, EXPAREL is promising because such
formulation leads to a slow release of bupivacaine, therefore,
allowing a longer duration of action and a slower uptake into
the systemic circulation, avoiding high plasma (and tissue)
concentrations [1].
Another DepoFoam product, DepoDur (morphine sul-
fate extended-release liposome injection), can exchange its
drugloadwithlidocainewhencoadministered[2],leadingto
changes in systemic exposure. We therefore explored this po-
tential with EXPAREL in a clinically relevant minipig model
mimicking wound inﬁltration.
Lidocainewithepinephrineiscommonlyusedforwound
inﬁltration prior to surgery [3, 4]. In clinical practice, the
use of a lidocaine-bupivacaine mixture has the theoretical
advantage of allowing a smaller dose of each agent than if
they were used alone. Lidocaine is expected to provide fast-
er onset of sensory blockade after local nerve block and may
be administered in the same ﬁeld in surgical patients. Epi-
nephrine decreases bleeding in the area of injection by con-
stricting blood vessels. As a result, the use of epinephrine as
a vasoconstrictor agent is expected to maximize any poten-
tial local interaction by decreasing local clearance from the
injection [5].
The combined additive toxicologic eﬀects of lidocaine
and bupivacaine on central nervous (CNS) and cardiovas-
cular (CV) systems have been reported [6–11], but there is a
paucity of data evaluating the potential for drug interaction,
from a pharmacokinetic (PK) perspective.
The objective of the present study was to quantify the
degree of drug interaction that may occur when EXPAREL
and lido are inﬁltrated subcutaneously (sc) within 5, 10, 20,
or 40 minutes of each other at clinically relevant doses and
concentrations.2 ISRN Pharmaceutics
Figure 1: Diagram showing the dose equally distributed as 6 serial
bolus injections along a 5cm virtual incision line.
The protocol included in vivo conditions that simulate
the sc inﬁltration in a wound. The skin of pigs has a layer
of sc tissue, which is very similar to that of man. The skin
morphology (tight adhesiveness of the skin to the underlying
structures), compared to rat, rabbit, or dog where the skin is
loose, and physiology makes the swine a preferred model for
extrapolation to humans [12–14].
Due to the clinical relevance of the miniature swine
model used in this study, the present data were expected
to provide a relevant prediction of the potential local
interaction of EXPAREL when administered with lidocaine
in humans. Therefore, dosing recommendations in a clinical
setting were proposed.
2.MaterialsandMethods
2.1. Materials
2.1.1. Description of DepoFoam Technology. The DepoFoam
drug delivery system is a proprietary, injectable technology
that provides a sustained release of therapeutic compounds.
The DepoFoam system consists of microscopic, polyhedral,
lipid-based particles composed of numerous nonconcentric,
aqueous chambers containing the drug in solution.
Each chamber in this multivesicular liposome is sepa-
rated from adjacent chambers by lipid membranes [15].
2.1.2. Test Article. DepoFoam bupivacaine (EXPAREL; bupi-
vacaine extended-release liposome injection using mul-
tivesicular DepoFoam technology), 15mg/mL (expressed
as anhydrous bupivacaine base) was provided by Pacira
Pharmaceuticals, Inc., San Diego, CA, USA. As needed,
EXPAREL was diluted with 0.9% sodium chloride injection
USP to achieve a target concentration of 7.5mg/mL.
2.1.3. Reference Product. Xylocaine-MPF, (1% or 2% lido-
caine HCl with 1:200,000 epinephrine) was manufactured
by AstraZeneca, Wilmington, DE, USA.
2.1.4. Animals. Male na¨ ıve Yucatan Miniature Swine were
received from Sinclair BioResources Auxvasse, MO, USA.
T h ea n i m a l sw e r e6t o1 7m o n t h so fa g eo na r r i v a l ,a n d2 4 –
50kg at the time of dosing.
2.2. Methods
2.2.1. Study Protocol. T h ep r o t o c o lw a sr e v i e w e da n d
approved by the Institutional Animal Care and Use Commit-
tee (IACUC) of Sinclair Research Center for compliance with
regulations prior to study initiation. This study complies
Area of dose administration
Figure 2: Diagram showing the approximate area where subcuta-
neous injections were administered on each animal (i.e., scapular
region).
with all applicable sections of the Final Rules of the Animal
Welfare Act regulation (9CFR).
Animals were housed in individual, stainless-steel,
metabolism cages throughout the study period. Animals
were fed once a day with free access to water. During a 5-
day acclimation period, the animals were trained to a sling
device. The animals were not fasted overnight before dose
administration.
Sixty (60) male Yucatan Swine were randomized into 20
groups (N = 3/group). EXPAREL and/or lidocaine solution
1% or 2% (with epinephrine 1:200,000) was administered
sc at dose levels of either 1 or 2mg/kg. Bupivacaine was
incorporated into the sustained release material at a percent
loading of 1.5% by weight and further diluted with 0.9%
sterile sodium chloride to achieve the desired concentration.
Diﬀerent dose regimen combinations were studied. Control
groups with equivalent dose and volume were used to allow
useful comparison with the test formulation.
Groups 1 and 2 received EXPAREL alone (0.27mL/kg).
Groups 3 and 4 received lidocaine alone (0.2mL/kg). All
remaining groups received 0.2mL/kg lidocaine followed by
0.27mL/kg EXPAREL at a given interval of time later (5, 10,
20, or 40 minutes).
Since the recommended dose volume is approximately
2mL/cm, the dose was equally distributed as 6 serial bo-
lus injections along a 5cm virtual incision line in the scapu-
lar region (Figures 1 and 2). Each injection was made per-
pendicular to the skin surface (i.e., directing the needle ap-
proximately 90 degrees), and each bolus was injected slowly
(over 5 seconds) in the exact same spot as trailing injections
along the line. The ﬁrst injection (start of dosing) was
performed beginning proximal to the line. The needle was
redirected slightly more distal than the ﬁrst pass of the
needle, and the process was repeated a second time withISRN Pharmaceutics 3
Table 1: Pharmacokinetic parameters for lidocaine after adminis-
tration of EXPAREL and lidocaine/epinephrine solution (4:4 dose
ratio).
Time
interval
(min)a
Parameters for plasma lidocaine
(% change from lidocaine control)
AUC0−24hr (hr·ng/mL) Cmax (ng/mL)
0 3,490 ±1,160 1,070 ±82.9
5 5,170 ±1,860 (+48%) 18,600 ±5,472 (+1,640%)
10 1,720 ±202 (−51%) 1,200 ± 104 (+12%)
20 2,290 ±269 (−34%) 723 ±206 (−32%)
40 1,980 ±827 (−76%) 774 ±127 (−28%)
aN = 3 per group. Please refer to Section 2.2 for experimental details.
another aliquot. All injections in a series were completed
within 30–40 seconds. Blood samples were collected at
predose, 5, 10, 15, 30 minutes, and 1, 2, 4, 6, 8, 12, 24, 48,
72, and 96 hours postdosing.
2.2.2. Pharmacokinetic Assessment. Plasma concentrations
were simultaneously analyzed by ABC Laboratories, Colum-
bia,MO,USA,usingavalidatedLC-MS/MSassay.Themeth-
od is selective for the quantiﬁcation of bupivacaine and lido-
caine in K3EDTA plasma in the concentrations ranging from
0.25 to 100ng/mL for each analyte. Depending on the time
interval, between 5 and 40 minutes of plasma data for lido-
caine were not collected since blood collection began after
EXPAREL administration. This was taken into account when
performing comparisons among groups. Systemic exposure
parameters for lidocaine in the presence of bupivacaine
represent minimal estimates only.
The PK parameters were evaluated by a noncompart-
mental model using WinNonlin, version 5.0 (Pharsight
Corp., Mountain View, CA, USA). The PK parameters in-
cluded maximum plasma concentration (Cmax), time at
which the Cmax occurred (tmax), and area under the plasma
concentration-time data (AUC0−t). The appropriate group
mean values and standard deviation (SD) were calculated
from the individual data.
3. Results andDiscussion
3.1. Results. The PK results are shown in Tables 1 and 2 and
Figures 3, 4,a n d5. The most signiﬁcant eﬀects are high-
lighted below.
All doses were well tolerated in this model. Most diﬀer-
ences in plasma parameters were clinically insigniﬁcant and
were attributed to biological variations in individual re-
sponses.
Notably, there was no clinically meaningful diﬀerence in
themeansystemicplasmaexposuretoeitherlidocaineorbu-
pivacaine when EXPAREL was given 20 minutes or longer
afterlidocaineadministrationinstudiesusing4mg/kgoflid-
ocaine and EXPAREL.
While systemic exposure to lidocaine or bupivacaine
was not increased when EXPAREL was administered 20 mi-
nutes or longer following lidocaine administration, when the
Table 2: Pharmacokinetic parameters for bupivacaine after admin-
istrationofEXPARELandlidocaine/epinephrinesolution(4:4dose
ratio).
Time
interval
(min)a
Parameters for plasma bupivacaine
(% change from bupivacaine control)
AUC0−24hr (hr·ng/mL) Cmax (ng/mL)
0 2,240 ±721 519 ±230
5b 4,370 (+95%)
(2,980–5,770)
5,730 (+1,000%)
(3,690–7,770)
10 3,370 ±1,980 (+50%) 865 ± 488 (+67%)
20 2,100 ±445 (−6%) 412 ±113 (−21%)
40 2,150 ±410 (−4%) 422 ±119 (−19%)
aN = 3 per group (unless noted); bN = 2; one animal received 55% of
the intended dose of EXPAREL. Data from this animal were not used in
calculation of means.
interval was less than 20 minutes there were increases in sys-
temic exposure. At the early timepoints (5 and 10 minutes),
there was a marked diﬀerence in plasma lidocaine and/or
bupivacaine (Cmax,A U C 0−24hr) in animals receiving larger
doses of more concentrated formulations.
Whenthehighdoseoflidocainewasfollowedbythehigh
dose of EXPAREL (4mg/kg each) by 5–10 minutes, the sys-
temic exposure to lidocaine was increased over the exposure
seen when the high dose of lidocaine was administered alone
(Table 1)( Cmax 1,070 ± 82.9 versus 18,600 ± 5,472ng/mL
and AUC0−24hr 872 ± 290 versus 1,290 ± 465hr·ng/mL;
Cmax ↑ 1,640%; AUC0−24hr ↑ 48%).
When the high dose of lidocaine was followed by the
high dose of EXPAREL (4mg/kg each) by 5–10 minutes,
Cmax of bupivacaine (EXPAREL) was increased 67–1,000%
(519±230versus865±488and5,730ng/mL)andAUC0−24hr
was 50–95% higher (2,240±721hr·ng/mL versus 4,370 and
3,370 ± 1,980hr·ng/mL) compared to when EXPAREL was
administered alone (Table 2).
3.2. Discussion. Drug interactions are signiﬁcant risk factors,
especially, in surgical patients receiving multimodal analge-
sia. The magnitude of these interactions depends on a mul-
titude of factors including dose volume, dose concentration,
injection method, and timing/sequence of administration.
In the present study, we evaluated the degree of drug
interaction that may occur when EXPAREL is inﬁltrated 5,
10,20,or40minutesafteraninjectionoflidocaineatvarious
clinically relevant dose ratios and drug concentrations.
We used a clinically relevant animal model with in vivo
conditionsthatsimulatethescinﬁltrationinawound.Aspe-
cial injection inﬁltration procedure was used to facilitate
close contact between lidocaine and bupivacaine while mini-
mizing the risk of disruption of lipid vesicles and other dis-
turbances of the injection area. This model was considered
particularly relevant for this type of investigation due to skin
similarities between the minipig and humans [12–14]. The
doses selected in our studies were based on these recom-
mendations. Therecommended guideline in pigs is lidocaine
given at 1–4mg/kg maximum dose mixed with conventional
bupivacaine 1-2mg/kg before the incision is made [16].4 ISRN Pharmaceutics
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Figure 3: Mean systemic exposure parameters (±SD) for plasma lidocaine (a) and bupivacaine (b) after high (4mg/kg) subcutaneous dose
of lidocaine/epinephrine and EXPAREL (N = 3/group unless noted). Series 1: AUC0−24hr (ng/mL·hr). Series 2: Cmax (ng/mL). Notes: SD
was not calculated for mean plasma bupivacaine concentrations at 5 minutes (N = 2) because one animal received 55% of the intended
dose of EXPAREL; therefore, data from this animal were not used in calculation of means; individual values for AUC0−24hr = 2,980 and
5,770ng/mL·hr and for Cmax = 3,690 and 7,770ng/mL.
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Figure 4: Mean systemic exposure parameters (±SD) for plasma
lidocaine after high (4mg/kg) subcutaneous dose of lido-
caine/epinephrine and EXPAREL (N = 3/group).
When lidocaine is used for regional nerve blocks, plasma
levels are usually 3,000–5,000ng/mL; toxicities may be ob-
servedat6,000ng/mL,butmorecommonlyoccuroncelevels
exceed 10,000ng/mL. Therapeutic levels are usually 700–
1,000ng/mL while plasma threshold associated with system-
ic toxicity is 2,000 to 4,000ng/mL for bupivacaine [17, 18].
Asthetoxicityofbupivacaineisknowntobegenerallyassoci-
ated with its Cmax, EXPAREL may be safer than unencapsu-
lated bupivacaine solution at the same dose by allowing for a
longer presence of bupivacaine at lower systemic peak levels.
There was no clinically meaningful diﬀerence in the
mean systemic plasma exposure to either lidocaine or bupi-
vacaine when EXPAREL was given 20 minutes or longer after
lidocaine administration in studies using 4mg/kg of lido-
caine and EXPAREL. At the early timepoints (5 and 10 mi-
nutes), there was a marked diﬀerence in plasma lidocaine
and/or bupivacaine (Cmax,A U C 0−24hr) in animals receiving
larger doses of more concentrated formulations.
It should be noted that the dosing procedure selected
for this study maximizes the potential risk of drug interfer-
ence. The injected concentrated formulations were in close
proximity of each other, especially after being inﬁltrated in
the same ﬁeld and within a short time interval. The high-
doseratio(4:4)resultshighlightthepossibilityofaclinically
relevant PK interference when EXPAREL is inﬁltrated within
a shorter time interval following lidocaine solution. The in-
volvement of epinephrine to vasoconstrict most likely allows
greater interaction of the concentrated compounds at the
injection sites.
It is not yet clear which precise mechanism(s) of action
are involved in this model. The physiological mechanism is
based in part upon the higher aﬃnity of lidocaine to the De-
poFoam. It is likely that the local interaction is inﬂuenced by
diluting/mixing eﬀects of the exposed sites in the presence
of both formulations. It is also possible that, at shorter time
intervals, increasing local blood ﬂow accelerates systemic
absorption of the injected formulation(s) since the vascular
eﬀects of lidocaine and bupivacaine are dynamic and depen-
dent on concentration and time [19–22].
In summary, there was no increase in either drug when
the administration of EXPAREL was delayed by 20 or 40
minutes after the injection of the lidocaine solution. WhileISRN Pharmaceutics 5
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Figure 5: Systemic exposure parameters (±SD) for plasma
bupivacaine after high (4mg/kg) subcutaneous dose of lido-
caine/epinephrine and EXPAREL (N = 3/group unless noted).
Notes: SD was not calculated for bupivacaine at 5 minutes (N = 2,
AUC = 2,980 and 5,770ng/mL·h; Cmax = 3,690 and 7,770ng/mL).
EXPAREL should not be admixed with lidocaine, adminis-
tration of EXPAREL after at least 20 minutes following local
administration of lidocaine did not increase the release of
either drug. All other lidocaine/EXPAREL drug interaction
eﬀects were not considered clinically meaningful.
4. Conclusions
Based on the preclinical data, we conclude that local admin-
istration of EXPAREL after at least 20 minutes following
local administration of lidocaine did not increase systemic
exposure of either drug.
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